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XIAP-targeting drugs re-sensitize PIK3CA-mutated
colorectal cancer cells for death receptor-induced
apoptosis
M Ehrenschwender*,1, S Bittner1, K Seibold1 and H Wajant2
Mutations in the oncogenic PIK3CA gene are found in 10–20% of colorectal cancers (CRCs) and are associated with poor
prognosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic TRAIL death receptor antibodies
emerged as promising anti-neoplastic therapeutics, but to date failed to prove their capability in the clinical setting as especially
primary tumors exhibit high rates of TRAIL resistance. In our study, we investigated the molecular mechanisms underlying TRAIL
resistance in CRC cells with a mutant PIK3CA (PIK3CA-mut) gene. We show that inhibition of the constitutively active
phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway only partially overcame TRAIL resistance in PIK3CA-mut-protected
HCT116 cells, although synergistic effects of TRAIL plus PI3K, Akt or cyclin-dependent kinase (CDK) inhibitors could be noted.
In sharp contrast, TRAIL triggered full-blown cell death induction in HCT116 PIK3CA-mut cells treated with proteasome inhibitors
such as bortezomib and MG132. At the molecular level, resistance of HCT116 PIK3CA-mut cells against TRAIL was reflected by
impaired caspase-3 activation and we provide evidence for a crucial involvement of the E3-ligase X-linked inhibitor of apoptosis
protein (XIAP) therein. Drugs interfering with the activity and/or the expression of XIAP, such as the second mitochondria-derived
activator of caspase mimetic BV6 and mithramycin-A, completely restored TRAIL sensitivity in PIK3CA-mut-protected HCT116 cells
independent of a functional mitochondrial cell death pathway. Importantly, proteasome inhibitors and XIAP-targeting agents also
sensitized other CRC cell lines with mutated PIK3CA for TRAIL-induced cell death. Together, our data suggest that proteasome- or
XIAP-targeting drugs offer a novel therapeutic approach to overcome TRAIL resistance in PIK3CA-mutated CRC.
Cell Death and Disease (2014) 5, e1570; doi:10.1038/cddis.2014.534; published online 11 December 2014
Colorectal cancer (CRC) is among the three most common
malignancies worldwide.1 Pathophysiologically, CRC devel-
opment been linked to the acquisition of oncogenic mutations
such as alterations in the phosphoinositide-3 kinase (PI3K)/
Akt pathway. PI3K converts phosphatidylinositol 4,5-bis-
phosphate to phosphatidylinositol 3,4,5-trisphosphate,
thereby generating a docking site for pleckstrin homology
domain containing proteins such as Akt/PKB. In CRC,
approximately 10–20% of tumors exhibit mutations in the
p110α catalytic subunit (predominantly H1047R and E545K
substitutions in thePIK3CA gene), causing constitutivePI3K/Akt
activation2 and worsening clinical outcome.3
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) emerged as a promising anti-cancer agent, capable
of selectively inducing cell death in tumor cells.4 TRAIL binding
to TRAIL receptor 1 (TRAIL-R1) or TRAIL-R2 induces formation
of a chain-like death-inducing signaling complex (DISC). This
allows stepwise caspase-8 activation and initiates a cascade of
proteolytic cleavage events finally activating caspase-3 and
triggering the execution phase of apoptosis.
In so-called type I cells, initial caspase-8-mediated cleavage
of caspase-3 efficiently triggers further autocatalytic caspase-3
processing to the mature heterotetrameric p12-p17 molecule.
In type II cells, however, X-linked inhibitor of apoptosis protein
(XIAP) inhibits processing of the caspase-3 p19 intermediate to
the p17 subunit of the mature enzyme. Death receptor-induced
apoptosis in these cells therefore relies on a mitochondria-
dependent amplification loop that is triggered by caspase-8-
mediated cleavage of the BH3-interacting domain death
agonist (Bid) to tBid.5 tBid activates Bcl2-associated X protein
(Bax) and Bcl2-antagonist/killer (Bak), enabling pore-formation
in the outer mitochondrial membrane and release of apopto-
genic factors such as cytochrome c and second mitochondria-
derived activator of caspase (SMAC).6 The pro-apoptotic effect
is at least twofold: cytochrome c associates with apoptotic
protease-activating factor 1 (Apaf-1), forming a molecular
scaffold for caspase-9 activation (‘apoptosome’), which in turn
boosts downstream effector caspase activation. Synergistically,
SMAC neutralizes cytosolic inhibitors of apoptosis proteins
(IAPs), such as cIAP1, cIAP2 and especially XIAP.7
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High levels of IAPs or deregulated expression of Bcl2 family
proteins are common in human cancers and often confer
apoptosis resistance. This hampers efficacy of TRAIL-based
therapies and to date, the therapeutic benefit of TRAIL in
clinical trials is indeed rather limited.8
We have recently found that mutantPIK3CA licensed TRAIL
and CD95L to induce an amoeboid morphology in CRC cells,
which is associated with increased invasiveness in vitro.9
Here, we show that targeting of the aberrantly active PI3K/Akt
signaling pathway in TRAIL resistant, PIK3CA-mutated CRC
cells only partially restored death receptor-triggered apoptosis
induction. We identified impaired caspase-3 maturation by
XIAP as the underlying molecular mechanism of TRAIL
resistance in HCT116 PIK3CA-mut cells. Inhibition of XIAP
or the proteasome efficiently restored TRAIL sensitivity
irrespective of mitochondria-dependent death signal amplifi-
cation. Together, our results indicate that targeting XIAPor the
proteasome in CRC with PIK3CA mutations may offer a
promising strategy to exploit the therapeutic potential of TRAIL
in cancer therapy.
Results
Mutant PIK3CA shifts TRAIL and Fc-CD95L signaling
from apoptosis induction to pro-survival signaling. Gene
targeting of PIK3CA in the CRC cell line HCT116 revealed
that exclusive expression of a PIK3CA allele harboring an
activating H1047R substitution (HCT116 PIK3CA-mut) in
exon 20 conferred resistance to TRAIL-induced apoptosis
(Figure 1a).9,10 In sharp contrast, the isogenic cell line with a
wild-type PIK3CA allele (HCT116 PIK3CA-wt) died in a dose-
dependent manner after TRAIL stimulation (Figure 1a; ED50-
value ~10 ng/mL). Importantly, Samuels et al. reported
TRAIL resistance in two PIK3CA mutant clones,10 thereby
ruling out simple clone-to-clone variations. PIK3CA-mut-
mediated protection was not limited to TRAIL, but also
observable upon treatment with Fc-CD95L (Figure 1b). This
suggested that the PIK3CA-mut-granted resistance is not
restricted to a single death receptor/ligand pair, but acts as a
more general protective mechanism against death receptor-
induced apoptosis.
Beside cell death induction, TRAIL-R1/-R2 and CD95 also
strongly activate pro-inflammatory and pro-survival pathways,
especially when cell death is blocked.11,12 We therefore
investigated pro-inflammatory TRAIL- and Fc-CD95L-
triggered responses in HCT116 PIK3CA-wt and HCT116
PIK3CA-mut cells. In principle, no differences regarding
activation of the mitogen-activated protein kinases, JNK, p38
and ERK in both cell lines (Figures 2a and b) were observed.
Caspase inhibition using zVAD-fmk barely affected early but
almost completely abolished sustained TRAIL-induced JNK
activation. This presumably reflects previously reported
differences in the caspase dependency of the early and late
phase of death receptor-induced biphasic JNK activation.13,14
Consistently, TRAIL- and Fc-CD95L-induced caspase activa-
tion in apoptosis-susceptible HCT116 PIK3CA-wt cells was
accompanied by high phospho-JNK levels.
We observed robust NF-κB activation and induction of the
NF-κB target gene IL-8 in HCT116 PIK3CA-mut cells
(Figure 2c). In HCT116 PIK3CA-wt cells, TRAIL or Fc-
CD95L challenge predominately induced apoptosis and IL-8
production was critically dependent on blocking caspase
activation with zVAD-fmk (Figure 2c). Importantly, the impaired
NF-κB response in HCT116 PIK3CA-wt cells upon TRAIL or
Fc-CD95L treatment did neither reflect gross abnormalities in
the NF-κB signaling pathway per se, nor cell line-specific
(HCT116 PIK3CA-wt versus PIK3CA-mut) differences in
TRAIL receptor- or CD95-associated signaling pathways for
the following reasons: treatment of HCT116 PIK3CA-wt and
the PIK3CA-mut counterparts with the primarily pro-
inflammatory ligand TNF exhibited comparable levels of
phospho-IκBα, thereby ruling out general defects in the
activation of the NF-κB pathway (Figure 2d). Additionally,
induction of IL-8 in zVAD-fmk-protected HCT116 PIK3CA-wt
cells after TRAIL or Fc-CD95L treatment was at least as
efficient as in HCT116 PIK3CA-mut cells (Figure 2c).
Together, our findings demonstrated that TRAIL and
Fc-CD95L induced a pro-inflammatory response in
apoptosis-resistant HCT116 PIK3CA-mut cells.
Pharmacological inhibition of Akt, PI3K and CDK only
partially sensitizes PIK3CA-mut-protected cells to TRAIL.
We next investigated mechanisms to overcome TRAIL
resistance in HCT116 PIK3CA-mut cells. As previous work
Figure 1 PIK3CA-mut renders HCT116 cells resistant to TRAIL- and Fc-CD95L-
induced cell death. HCT116 PIK3CA-wt and HCT116 PIK3CA-mut cells were seeded
in 96-well plates and challenged the next day in triplicates with the indicated
concentrations of (a) TRAIL and (b) Fc-CD95L. Cell viability was determined by 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide staining 18 h after
stimulation. Results are given as mean values±S.D. from three experiments
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demonstrated constitutive activation of the PI3K/Akt signaling
axis in HCT116 PIK3CA-mut cells,10,15 we evaluated the
contribution of this pathway to TRAIL resistance. Pre-
treatment of HCT116 PIK3CA-mut cells with the Akt inhibitors
triciribine (Figure 3a) or deguelin (Figure 3b) resulted only in a
partial re-sensitization to TRAIL-induced cell death. Additionally,
increasing concentrations of triciribine and deguelin exhibited
cytotoxic effects themselves. This potentially hampers
recognition of true synergistic effects of TRAIL plus Akt
inhibitor treatment. We therefore quantitatively assessed
synergism by calculating a combination index (CI) for all
used TRAIL plus inhibitor combinations. Briefly, CI-values41
indicate a synergistic effect of TRAIL in combination with a
pharmacological inhibitor.13 Decreasing CI-values correlate
with enhanced synergism of the two compounds. CI-values
above 1 are indicative for antagonism.
Figure 2 TRAIL and Fc-CD95L elicit a pro-inflammatory response in PIK3CA-mut-protected cells. (a, b and d) HCT116 PIK3CA-wt and HCT116 PIK3CA-mut cells were
stimulated with (a) TRAIL (50 ng/mL), (b) Fc-CD95L (200 ng/mL) or (d) TNF (100 ng/mL) for the indicated periods of time in the presence and absence of the pan-caspase
inhibitor zVAD-fmk (100 μM, added 1 h before stimulation). Subsequently, cells were washed, lysed and analyzed by western blotting using antibodies specific for the indicated
proteins. Detection of β-actin served as a loading control. Lysates from HCT116 PIK3CA-wt and HCT116 PIK3CA-mut cells have been run on the same gel for each condition.
(c) HCT116 PIK3CA-wt and HCT PIK3CA-mut cells were seeded in triplicates in 96-well plates and challenged the next day with the indicated concentrations of TRAIL
or Fc-CD95L for 6 h in the presence and absence of zVAD-fmk (100 μM, added 1 h before stimulation). Supernatants were harvested and IL-8 levels were measured using ELISA.
Results given as mean and representative for two experiments performed. n.d., not detectable
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In terms of cell death induction, synergistic effects of TRAIL
combined with the Akt inhibitors triciribine (CI0.1 μM triciribine=
0.49, CI0.5 μM triciribine=0.51, CI2 μM triciribine= 0.52) and degue-
lin (CI-values of 0.34, 0.65 and 0.63 for 0.1 μM, 0.5 μM and
1 μM concentrations of deguelin, respectively) were observed
(Figures 3a and b, lower panel).
Similar observations were made when challenging HCT116
PIK3CA-mut cells with TRAIL in the presence of PI3K-
inhibiting molecules. Wortmannin plus TRAIL exhibited
synergistic CI-values (Figure 3c, lower panel) for wortmannin
concentrations up to 1 μM (CI0.1 μM wortmannin= 0.35,
CI1 μM wortmannin=0.59), but this synergistic effect was lost at
higher wortmannin concentrations (CI5 μM wortmannin= 1.55).
Ly294002, another PI3K inhibitor, also acted synergistically
with TRAIL in concentrations up to 20 μM (CI10 μM Ly294002=
0.53, CI20 μM Ly294002=0.81). Again, increased cytotoxic
effects by Ly294002 itself were reflected by higher CI-values
(CI40 μM Ly294002=1.09) and correlated with observations from
the corresponding viability assays (Figure 3d). A recent report
demonstrated that TRAIL resistance could be overcome by
inhibition of CDK 9.8 Combining TRAIL with the CDK-
interfering agent roscovitine (Figure 3e) revealed synergistic
Figure 3 Pharmacological targeting of PI3K, Akt and CDKs only partially sensitizes HCT116 PIK3CA-mut cells toward TRAIL-induced cell death. HCT116 PIK3CA-mut cells
were seeded in triplicates in 96-well plates and stimulated the next day with 125 ng/mL TRAIL in the presence and absence of (a) triciribine, (b) deguelin, (c) wortmannin, (d)
Ly294002 or (e) roscovitine. Inhibitors were added 1 h before TRAIL stimulation. After 18 h, cell viability was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide staining. For each combination of TRAIL plus inhibitor, the corresponding combination index (CI) value was calculated. CI-values41 indicate a synergistic effect (see
also Materials and Methods section).13 Results for the viability assays are given as mean and representative for two experiments performed. For calculation of CI-values, means
derived from the viability assays were used
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CI-values (CI5 μM roscovitine= 0.67, CI10 μM roscovitine=0.48,
CI15 μM roscovitine=0.64).
Importantly, although we were able to clearly demonstrate
synergistic effects of combinatorial treatments of TRAIL and
an Akt, PI3K or CDK inhibitor, the re-sensitization to TRAIL-
induced cell death was only partial. As robust cell death
induction in transformed cells is crucial for effective TRAIL-
based anti-cancer therapy, we concluded that interfering with
the PI3K/Akt signaling axis or CDKs is most probably
insufficient to fully exploit the therapeutic potential of TRAIL
in PIK3CA-mutant CRC cells.
Proteasome inhibition fully restores TRAIL-mediated cell
death induction in HCT 116 PIK3CA-mut cells. Inhibition
of the proteasome has been found to break apoptosis
resistance in a variety of tumor entities including CRC.14
We therefore investigated whether blockade of the ubiquitin-
proteasome system affects TRAIL-induced cell death in
HCT116 PIK3CA-mut cells. Indeed, pre-treatment with the
proteasome inhibitors bortezomib or MG132 resulted in
almost full-blown cell death induction (Figure 4a, upper
panel), whereas the proteasome inhibitors alone showed only
modest cytotoxic activity. Accordingly, the CI-values
(Figure 4a, lower panel) indicated a very strong synergism
for TRAIL in combination with bortezomib (CI12.5 ng/mL TRAIL=
0.01, CI125 ng/mL TRAIL= 0.01) and MG132 (CI12.5 ng/mL TRAIL=
0.14, CI125 ng/mL TRAIL=0.25). Importantly, sensitization for
TRAIL-induced cell death by proteasome inhibition was not
restricted to HCT116 PIK3CA-mut cells and was also evident
in the PIK3CA-mutant CRC cell line LS-174T (H1047R
substitution, CI-values from 0.21 to 0.48; Figure 4b).
Caspases are the predominant executors of TRAIL-induced
cell death and we therefore analyzed caspase activation in
HCT116 PIK3CA-mut cells following TRAIL challenge.
Whereas caspase-8 was completely processed, finally yield-
ing the active p18 fragment (Figure 4c), processing of
caspase-3 stopped at the inactive p19 intermediate. Treat-
ment of HCT116 PIK3CA-mut cells with Fc-CD95L revealed
similar results, thereby arguing against a TRAIL-R1/-R2-
restricted phenomenon. These findings are in accordance
with our previous work that localized blockade of the apoptotic
cascade in HCT116 PIK3CA-mut cells downstream of DISC
formation and caspase-8 activation.9 Interestingly, pre-
treatment of PIK3CA-mut-protected cells with bortezomib
licensed TRAIL or Fc-CD95L to complete processing of
caspase-3 with concomitant cleavage of PARP, an indicator
for ongoing apoptosis. Of note, sensitization toward TRAIL-
induced cell death did not depend on the pro-apoptotic protein
Bax, as Bax expression in HCT116 PIK3CA-mut cells was
virtually absent compared with HCT116 PIK3CA-wt cells and
did not change upon proteasome inhibition (Figure 4c).
Reduced Bax expression levels in CRC cells harboring
activating PIK3CA-mutations have been described earlier,15
but the relevance for cell death induction when the ubiquitin-
proteasome system is blocked remained obscure.
Taken together, our data provide evidence that impaired
caspase-3 processing is causative for hindering TRAIL- or Fc-
CD95L-induced cell death in HCT116 PIK3CA-mut cells.
Proteasome inhibition efficiently overcomes the blockade in
caspase-3 activation and enables robust, Bax-independent
cell death induction.
TRAIL stimulation reduces cellular XIAP levels in
bortezomib-treated PIK3CA-mut-protected cells. The
sensitizing effect of proteasome inhibitors to cell death in
various malignant tumors has been linked to changes in
cellular levels of pro- or anti-apoptotic proteins. In CRC, the
underlying molecular mechanism is poorly understood.
Therefore, we analyzed cellular levels of pro- and anti-
apoptotic proteins in HCT116 PIK3CA-mut cells upon TRAIL
treatment in the presence and absence of bortezomib
(Figure 5a, left panel). We did not observe accumulation of
apoptosis-promoting BH3-only proteins such as Puma and
Bcl2-interacting mediator of cell death (Bim), but detected
TRAIL-induced cleavage of Bid into tBid, which was even
more pronounced with bortezomib. Concomitantly, cleavage
of the pro-form of caspase-9 was observable, indicating
involvement of the intrinsic, mitochondria-dependent cell
death pathway. This was astonishing, because HCT116
PIK3CA-mut cells are virtually Bax deficient (Figure 4c).15
Therefore, formation of a pore complex releasing cytochrome
c for caspase-9 activation via the apoptosome should be
hampered. We also analyzed the expression level of Bak, an
alternative channel-forming protein in the outer mitochondria
membrane. Interestingly, Bak levels upon bortezomib and
TRAIL treatment decreased by ~ 50% (Figure 5b), arguing
against a critical role of the Bax/Bak system in the
bortezomib-mediated sensitization of PIK3CA-mut-protected
HCT116 cells to TRAIL. However, as a previous report found
that TRAIL-induced cell death under proteasome inhibition
crucially depended on a functional intrinsic apoptotic
pathway,16 we assessed the role of the mitochondria-
dependent cell death pathway for TRAIL susceptibility in
bortezomib-treated HCT116 PIK3CA-mut cells.
Apoptosome-mediated caspase-9 activation is central for
intrinsic cell death induction. We therefore hypothesized that
knockdown of caspase-9 should rescue bortezomib-treated
HCT116 PIK3CA-mut cells from TRAIL-induced cell death. To
our surprise, knockdown of caspase-9 failed to do so
(Figure 5c), indicating that in our experimental setting
caspase-9 and Bid cleavage represented rather an epiphe-
nomenon of massively ongoing caspase-mediated proteolysis
but not a driving force for apoptosis induction. In fact, cleavage
of caspase-9 is not only unnecessary for its activation but it is
also insufficient to produce an active enzyme.17
To that point, elevations in apoptosis-promoting molecules
seemed unlikely to be the molecular basis for bortezomib-
induced TRAIL sensitization. Consequently, we analyzed
changes in the levels of anti-apoptotic proteins in HCT116
PIK3CA-mut cells upon treatment with TRAIL plus bortezomib
(Figure 5a, right panel). Although bortezomib is generally
capable to decrease levels of anti-apoptotic proteins such as
cFLIP,18 no significant changes in the levels of cFLIP, long
splice variant of Bcl-X (Bcl-XL) and Survivin were detectable in
our cellular system (Figure 5a). Of note, bortezomib increased
myeloid cell leukemia 1 (Mcl-1) expression approximately 2.7-
fold and approximately 15-fold in combination with TRAIL
(Figure 5b). This result was unexpected as the strong
upregulation of an anti-apoptotic protein obviously failed to
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Figure 4 Proteasome inhibition restores TRAIL susceptibility in HCT 116 PIK3CA-mut cells and allows full-blown caspase-3 processing. (a) HCT116 PIK3CA-mut cells were
seeded in triplicates in 96-well plates and challenged the next day with 12.5 or 125 ng/mL TRAIL in the presence and absence of 10 nM bortezomib (borte) or 100 nM MG132.
Proteasome inhibitors were added 1 h before TRAIL treatment. Cell viability was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) staining after 18 h.
For each combination of TRAIL plus proteasome inhibitor, the corresponding CI-value was calculated. Results for the viability assays are given as mean and representative for two
experiments performed. For calculation of CI-values, means derived from the viability assays were used. (b) LS174-T cells were seeded in triplicates in 96-well plates and challenged
the next day with 4 or 8 ng/mLTRAIL in the presence and absence of 80 nM borte. After 18 h, cell viability was determined by MTT staining and the corresponding CI-values were
calculated. Results for the viability assays are given as mean and representative for two experiments performed. For calculation of CI-values, means derived from the viability assays
were used. (c) HCT116 PIK3CA-mut cells were stimulated with TRAIL (125 ng/mL) or Fc-CD95L (200 ng/mL) overnight in the presence and absence of borte (10 nM, added 1 h
before stimulation). Cells were harvested, washed and subsequently analyzed by western blotting using antibodies specific for the indicated proteins. Detection of β-actin served as a
loading control. HCT116 PIK3CA-wt cells (first lane) were included to demonstrate cell line-specific differences in Bax expression between PIK3CA-mut and PIK3CA-wt cells
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rescue bortezomib-treated HCT116 PIK3CA-mut cells from
TRAIL-induced cell death. Enhanced expression of Mcl-1 in
HCT116 PIK3CA-mut cells was solely dependent on TRAIL.
Interfering with PI3K/Akt pathway using Ly294002 or
bortezomib-mediated blockade of the proteasome had no
negative effect on Mcl-1 expression, although shutdown
efficiency of the targeted pathways was confirmed
(Figure 5d, lower panel) by decrease of phospho-Akt
(Ly294002) and accumulation of phospho-IκBα following
TRAIL stimulation (bortezomib).
Beside changes in Mcl-1 levels, TRAIL challenge of
bortezomib-treated HCT116 PIK3CA-mut cells also reduced
cellular XIAP levels (Figure 5a, right panel) by ~ 50%
(Figure 5b). Notably, cellular XIAP levels showed no significant
differences between HCT116 PIK3CA-wt and PIK3CA-mut
cells (Figure 5e).
In sum, bortezomib alone did not significantly change the
levels of the pro- and anti-apoptotic proteins we surveyed.
Intriguingly, TRAIL challenge of proteasome-blocked HCT116
PIK3CA-mut cells reduced XIAP levels and was accompanied
by complete caspase-3 activation and apoptosis induction
(Figure 4). XIAP has been implicated in the regulation of
caspase-3 processing, essentially allowing cleavage of
pro-caspase-3 to the p19 intermediate but blocking
further processing to the fully active fragment p17.19 As this
strikingly resembled blocked caspase-3 activation in HCT116
Figure 5 TRAIL lowers XIAP levels and potently induces cell death in proteasome-blocked HCT116 PIK3CA-mut cells. (a) HCT116 PIK3CA-mut cells were challenged with
125 ng/mL TRAIL for 6 h in the presence and absence of 10 nM bortezomib (borte) or left untreated. Cells were harvested, lysed and subsequently analyzed using western
blotting with specific antibodies for the indicated proteins. (b) Decrease in Bak and XIAP levels as well as increase in Mcl-1 levels were quantified using densitometry. (c) HCT116
PIK3CA-mut cells were seeded in six-well plates and transfected with caspase-9-specific or non-targeting siRNA oligonucleotides the next day. 24 h after transfection, cells were
transferred into 96-well plates and another 24 h later challenged in triplicates with different concentrations of TRAIL. Knockdown efficacy was controlled by western blotting using
specific antibodies 48 h after siRNA transfection. Results given as mean and representative for two experiments performed. (d) Upper panel: HCT116 PIK3CA-mut cells were
challenged with 125 ng/mL TRAIL in the presence and absence of the PI3K inhibitor Ly294002 (10 μM) and the proteasome inhibitor borte (10 nM). Subsequently, cells
were harvested, lysed and analyzed for Mcl-1 or β-actin using specific antibodies. Detection of β-actin served as a loading control. Lower panel: HCT116 PIK3CA-mut cells were
treated with PI3K inhibitor Ly294002 (2 h, 10 μM) or the proteasome inhibitor borte (10 nM). Borte-treated cells were subsequently challenged with TRAIL (50 ng/mL) for 2 h.
Cells were harvested and subjected to western blot analysis using antibodies with specificity for the indicated proteins. (e) XIAP levels in lysates from HCT116 PIK3CA-mut and
HCT116 PIK3CA-wt cells were analyzed using western blotting with specific antibodies for the indicated proteins. Detection of tubulin served as a loading control
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PIK3CA-mut cells, we hypothesized that XIAP holds a crucial
role in TRAIL resistance of PIK3CA-mut-protected cells.
Drugs interfering with expression and activity of XIAP
re-sensitize mutant PIK3CA CRC cells to TRAIL-induced
cell death. Next, we asked if lowering XIAP expression/
activity with molecules such as mithramycin-A (mith-A)20 or
the SMAC-mimetic BV621 sensitizes HCT116 PIK3CA-mut
cells to TRAIL. BV6 and mith-A reduced XIAP levels in
HCT116 PIK3CA-mut cells in a dose-dependent manner
(Figure 6a). For BV6, XIAP reduction has been attributed to
caspase-mediated cleavage during ongoing apoptosis.22
However, the mode of action potentially differs in HCT116
PIK3CA-mut cells, as BV6-reduced XIAP levels in the
presence of the pan-caspase inhibitor zVAD-fmk (Figure 6a,
right panel) and no XIAP cleavage products were detectable
(Figure 6a).
Lowering XIAP levels significantly sensitized PIK3CA-mut-
protected HCT116 cells to TRAIL-induced cell death
(Figure 6b). Of note, the ED50-value was approximately
4 ng/mL for TRAIL plus mithramycin and approximately 8 ng/
mL for TRAIL plus BV6, almost perfectly matching TRAIL-
susceptible HCT116 PIK3CA-wt cells (Figure 1a).9 In accor-
dance with the significantly enhanced TRAIL-induced loss of
viability of mithramycin or BV6 pre-treated PIK3CA-mut-
protected cells, the CI-values for combinatorial treatment
indicated strong synergistic effects, ranging from 0.01 to 0.03
for TRAIL plus mithramycin and from 0.46 to 0.11 for TRAIL
plus BV6 (Figure 6b, lower panel). TRAIL-induced cell death
was accompanied by complete caspase-3 processing upon
mith-A or BV6 pre-treatment (Figure 6c). Notably, TRAIL
concentrations as low as 8 ng/mL efficiently activated
caspase-3. Our findings were not restricted to HCT116
PIK3CA-mut cells. Mith-A and BV6 also robustly sensitized
LS-174T and DLD-1 to TRAIL-induced cell death with CI-
values ranging from 0.002 to 0.08 (Figure 6d). Likewise, BV6
and mith-A reduced XIAP levels in LS-174T (Figure 6e) and
DLD-1 cells (data not shown) in a dose-dependent manner
and allowed complete TRAIL-induced caspase-3 activation in
both cell lines (Figure 6e and data not shown).
Discussion
PIK3CA-mutations in CRC limit therapeutic options and are
associated with poor prognosis.3 Isogenic HCT116 cell lines
expressing solely a wild-type or mutant (H1047R) PIK3CA
allele exhibited a constitutively activated PI3K/Akt-pathway,
high-level resistance against TRAIL-induced cell death10 and
increased invasiveness in vitro and in vivo.9,15 TRAIL
resistance was essentially attributed to constitutive PI3K
activation and reduced Bax expression.15,23 We confirmed
that mutant PIK3CA shifts TRAIL and Fc-CD95L signaling
from cell death induction to pro-survival signaling via robust
NF-κB activation. The latter was poor in HCT116 PIK3CA-wt
cells (Figure 2c) and most likely attributable to efficient shut
down of the classical NFκB pathway through caspase-
mediated cleavage of signaling intermediates.24 In line with
this, rescuing TRAIL or Fc-CD95L-treated PIK3CA-wt cells
with the pan-caspase inhibitor zVAD-fmk allowed at least as
efficient NF-κB activation in HCT116 PIK3CA-wt compared
with HCT116 PIK3CA-mut cells (Figure 2c). Our findings have
a fundamental impact on therapeutic approaches toward
mutant PIK3CA-bearing CRC cells, as TRAIL-induced pro-
inflammatory signaling potentially fosters tumor formation and
has been associated with increased invasiveness in vitro.9
Consequently, TRAIL-based therapies in this tumor entity may
even be contraindicated unless TRAIL resistance can be
efficiently overcome.
To date, attempts to break TRAIL resistance included
among others blockade of NF-κB signaling, proteasome
inhibition and inhibition of histone deacetylases.25–27 In
HCT116 PIK3CA-mut cells, interfering with the activated
PI3K/Akt pathway significantly reduced cell survival under
growth factor deprivation stress.15 We therefore analyzed the
effect of PI3K, Akt and CDK inhibitors combined with TRAIL
and demonstrated a synergistic mode of action regarding cell
death induction (Figure 3). The observed synergism is
potentially a TRAIL-specific phenomenon, as in an earlier
study, treatment of mutant PIK3CA CRC cells with PI3K
inhibitors and cytotoxic drugs such as doxorubicin failed to
synergistically increase cell death induction, although prolif-
eration ceased.28 However, re-sensitization of HCT116
PIK3CA-mut cells to TRAIL with any of these inhibitors was
not full-blown but only partial. Potentially, nonspecific or
ineffective pharmacological inhibition could be causative for
inefficient sensitization but seemed unlikely, as multiple
inhibitors targeting the PI3K/Akt signaling axis used at various
concentrations revealed comparable results.
In any case, incomplete re-sensitization leaves the possi-
bility that TRAIL-based therapies might trigger tumorigenic
Figure 6 XIAP is essential for TRAIL resistance in HCT116 PIK3CA-mut cells. (a) HCT116 PIK3CA-mut cells were treated with the indicated concentrations of BV6 (left
panel) or mithramycin-A (mith-A; lower right panel) for 18 h. To block caspase activation in BV6-treated cells (upper right panel), zVAD-fmk (100 μM) was added 1 h before BV6
treatment. Subsequently, cells were harvested, lysed and analyzed by western blotting for the indicated proteins using specific antibodies. Detection of tubulin served as loading
control. (b) HCT116 PIK3CA-mut cells were seeded in 96-well plates and challenged the next day with the indicated concentrations of TRAIL in the presence and absence of mith-
A (500 nM, added 1 h before stimulation) or BV6 (12.5 μM, added 1 h before stimulation). 18 h after TRAIL challenge, cell viability was determined by 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide (MTT) staining. Results are given as mean and representative for two experiments, for calculation of CI-values, means derived from the viability
assays were used. (c) HCT116 PIK3CA-mut cells were treated with mith-A (500 nM, added 1 h before stimulation) or BV6 (12.5 μM, added 1 h before stimulation) and
subsequently challenged with 8 ng/mL TRAIL for 6 h. Cells were harvested, lysed and subsequently analyzed using western blotting with specific antibodies for the indicated
proteins. Detection of tubulin served as a loading control. (d) LS174-T and DLD-1 cells were seeded in 96-well plates and challenged the next day with the indicated
concentrations of TRAIL in the presence and absence of mith-A (500 nM, added 1 h before stimulation) or BV6 (25 μM, added 1 h before stimulation). 18 h after TRAIL challenge,
cell viability was determined by MTT staining. Results are given as mean and representative for two experiments, for calculation of CI-values, means derived from the viability
assays were used. (e) Upper panel: LS-174T cells were treated with the indicated concentrations of mith-A or BV6 for 18 h. Subsequently, cells were harvested, lysed and
analyzed by western blotting for the indicated proteins using specific antibodies. Detection of tubulin served as loading control. Lower panel: LS-174T cells were treated with
mith-A (500 nM, added 1 h before stimulation) or BV6 (25 μM, added 1 h before stimulation) and subsequently challenged with 8 ng/mLTRAIL for 6 h. Cells were harvested, lysed
and subsequently analyzed using western blotting with specific antibodies for the indicated proteins. Detection of tubulin served as a loading control
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effects in the surviving population. In order to find a more
efficient method to sensitize PIK3CA-mut-protected cells to
TRAIL, we examined the influence of proteasome inhibition in
combination with TRAIL treatment (Figure 4a). Cell viability
was barely affected by the proteasome inhibitors bortezomib
or MG132 alone. In sharp contrast, addition of TRAIL resulted
in nearly complete cell death induction, which was more
pronounced in the presence of bortezomib compared with
MG132. Importantly, bortezomib-mediated sensitization for
TRAIL-induced cell death was not restricted to HCT116
PIK3CA-mut cells but also occurred in the PIK3CA-mutant
CRC cell lines LS-174T and DLD-1.
Mechanistically, several models have been proposed to
explain TRAIL sensitization after proteasome-blockade, such
as (a) downregulation of the anti-apoptotic protein cFLIP with
subsequently enhanced activation of caspase-8;18 (b) stabi-
lization of the pro-apoptotic proteins Bax29 or tBid16 and (c)
increased levels of the pro-apoptotic BH3-only proteins Bik
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and Bim.30 However, none of these mechanisms was
applicable to the bortezomib-induced TRAIL sensitivity in
HCT116PIK3CA-mut cells, as in the presence and absence of
bortezomib and/or TRAIL (a) cFLIP levels (Figure 5a) as well
as (b) Bax levels (Figure 4c) remained constant; tBid
generation and caspase-9 cleavage were dispensable for cell
death induction (Figure 5c) and (c) Bim levels (Figure 5a) did
not change significantly (Bik was not detectable, data not
shown). Admittedly, a wide-scale proteomic analysis of
bortezomib-induced changes in the expression of pro- and
anti-apoptotic proteins might reveal additional candidates.
Surprisingly, despite robust TRAIL-induced cell death
induction in bortezomib-treated HCT116 PIK3CA-mut cells,
the anti-apoptotic protein Mcl-1 was significantly upregulated
(Figures 5a and b). Although bortezomib alone only modestly
increased Mcl-1 levels, TRAIL treatment was capable to
significantly enhance Mcl-1 expression independent of PI3K/
Akt or proteasome inhibition (Figure 5d). Accumulation of Mcl-
1 upon proteasome inhibition is in line with a previous study,
demonstrating an increase of this protein in various malignant
tumor cell lines (including CRC) upon MG132 treatment.31
Because of the accumulation of Mcl-1, proteasome inhibition
might not under all circumstances have anti-tumoral activity. In
fact, increased Mcl-1 levels in proteasome-blocked CRC31
and neuroblastoma cells32 elicited pro-tumoral or tumor-
protective effects. Mechanistically, Mcl-1 can bind to and
sequester Bak, thereby interfering with Bax/Bak-mediated
pore formation in the outer mitochondrial membrane and
inhibiting the mitochondrial cell death pathway.33 Even
massive TRAIL-induced upregulation of Mcl-1 in HCT116
PIK3CA-mut cells failed to prevent cell death in the presence
of bortezomib. This pointed to a mitochondria-independent
mode of bortezomib-mediated TRAIL sensitization, which is in
line with our finding that downregulation of caspase-9 did not
protect bortezomib-treated HCT116 PIK3CA-mut cells from
TRAIL-induced cell death. In sum, our results argued for a
bortezomib-granted but mitochondria-independent mode of
TRAIL-induced cell death.
Interestingly, HCT116 cells are considered to be type II
cells. According to our findings, however, TRAIL-induced cell
death in bortezomib-treated HCT116 PIK3CA-mut cells
resembled type I cells. Earlier reports demonstrated that in
the absence of TRAIL bortezomib-induced cell death depends
on Bax. Bax-deficient HCT116 cells are consequently
bortezomib resistant.34 In contrast, a recent study elegantly
showed that proteasome inhibitors effectively overcame
TRAIL resistance even in Bax- and Bax-/Bak-deficient
HCT116 cells with a dysfunctional mitochondrial cell death
pathway.35 These data suggested that bortezomib switched
themode of cell death from type II to type I. This resembled our
observations in PIK3CA-mut-protected HCT116 cells, as
bortezomib fully re-sensitized to TRAIL-induced cell death
independent of the intrinsic cell death pathway. But in contrast
to the cited study,35 HCT116 PIK3CA-mut cells are genetically
neither Bax- nor Bak-deficient.
Blocked caspase-3 activation upon TRAIL stimulation at the
level of the inactive p19 intermediate (Figure 4c) pointed to a
potential role of XIAP in death resistance of HCT116 PIK3CA-
mut cells. The p19 fragment but not the active p17 fragment of
caspase-3 is negatively regulated by XIAP.36 XIAP contains
three caspase-interacting BIR (baculovirus IAP repeat)
domains and is itself a substrate of caspase-8. Caspase-8-
generated cleavage fragments of XIAP inhibit further proces-
sing of caspase-3 intermediates36 by competitive binding of
BIR1 and BIR2 (BIR1-2) to a neo-epitope in the caspase-3 p19
fragment.19 This inhibition can be surmounted by robust
caspase-3 activation and cleavage of XIAP in a manner that
functionally inactivates the BIR1-2 fragment.36 In TRAIL-
resistant melanoma cells, for example, caspase-3-mediated
XIAP cleavage acts as a positive feedback loop that sensitizes
to TRAIL-induced cell death.37 In line with this, TRAIL-induced
caspase-3 activation in bortezomib, BV6 and mith-A pre-
treated HCT116 PIK3CA-mut cells further enhanced the
initially observed caspase-independent reduction of XIAP of
these drugs (Figures 5a and 6c). This presumably reflects
proteolytic cleavage of the caspase-3 substrate XIAP.
In addition to competitive caspase inhibition, the E3-ligase
activity of XIAP inhibits caspase-3 activation by ubiquitination
of the active p17 fragment with subsequent proteasomal
degradation.38 TRAIL stimulation of proteasome-blocked
HCT116 PIK3CA-mut cells resulted in the appearance of the
active caspase-3 p17 fragment (Figure 4c), indicating ongoing
proteasomal degradation in cells with intact ubiquitin-
proteasome system. TRAIL resistance in HCT116 PIK3CA-
mut cells might therefore be regulated through the E3-ligase
activity of XIAP.
Accordingly, decreasing cellular XIAP levels in HCT116
PIK3CA-mut, LS-174T and DLD-1 cells using the SMAC-
mimetic BV621 potently enhanced TRAIL sensitivity (Figures
6b and d) and was accompanied by complete TRAIL-induced
caspase-3 activation (Figures 6c and e). BV6 not only inhibits
XIAP but also induces autoubiquitination and proteasomal
degradation of cIAP1 and cIAP2,22 opening the possibility that
degradation of cIAP1 and cIAP2 rather than XIAP inhibition is
causative for the synergistic effect of BV6 and TRAIL. This
cannot be fully excluded, but seems unlikely as cIAP1 and
cIAP2 are only poor competitive inhibitors of caspase-3,39 and,
in contrast to XIAP, cIAP1 targets the p19 fragment not the p17
fragment of caspase-3 for proteasomal degradation.40 Mith-A
essentially lowers XIAP levels by blockade of Sp1-mediated
transcription20 and thus affects XIAP activity by a different
mechanism than BV6. This strengthens the idea that XIAP is the
most relevant target of BV6 in the enhancement of TRAIL-
induced cell death. Mith-A might possibly also affect other
apoptosis regulatory proteins beside XIAP. A more direct
evaluation of the relevance of XIAP using siRNA experiments
technically failed, however, becauseof poor knockdownefficacy.
Taken together, our study points to XIAP as a potential
druggable molecule to overcome of TRAIL resistance in
PIK3CA-mut-protected CRC cells (summarized in Figure 7).
Our data provide experimental evidence that combinatorial
treatment approaches with TRAIL- and XIAP-targeting mole-
cules such as SMAC mimetics or XIAP-selective agents
potentially extend the currently limited therapeutic options of
PIK3CA-mutated CRC.
Materials and Methods
Cell lines, antibodies and reagents. LS-174T and DLD-1 cells were
purchased from the German Collection of Microorganisms and Cell Culture (DSMZ,
Braunschweig, Germany). HCT116 PIK3CA-wt and HCT116 PIK3CA-mut cells
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were a kind gift from Bert Vogelstein (Johns Hopkins University, Baltimore, MA,
USA). These isogenic cell lines exclusively harbor either a wild-type (HCT116
PIK3CA-wt) or a mutated allele (H1047R, HCT116 PIK3CA-mut) for PIK3CA. Cells
were cultured in RPMI 1640 medium (PAA, Pasching, Austria) supplemented with
10% fetal calf serum (PAA). Fc-CD95L was produced in HEK293 cells and purified
by affinity chromatography targeting an internal Flag epitope. Protein G agarose
beads coupled to anti-Flag mAb were purchased from Sigma (Deisenhofen,
Germany). Human recombinant TRAIL was purchased from Apronex (Jesenice u
Prahy, Czech Republic). Roscovitine, Ly294002 and wortmannin were purchased
from Adipogen (Liestal, Switzerland), deguelin from Cayman chemicals (Ann Arbor,
MI, USA) and mith-A from AppliChem (Darmstadt, Germany). BV6 (originally
described in Varfolomeev et al.22) was synthesized as described elsewhere.41
zVAD-fmk was obtained from Bachem (Heidelberg, Germany), MG132 from Merck
(Darmstadt, Germany), bortezomib from US Biological (Swampscott, MA, USA).
Antibodies specific for caspase-3, caspase-8, caspase-9, JNK, phospho-JNK, ERK,
phospho-ERK, p38, phospho-p38, IκBα, phospho-IκBα, Puma, Bim, Bid, Bak,
cFLIP, Bcl-XL, Survivin, Mcl-1 and XIAP were purchased from Cell Signaling
(Beverly, MA, USA). Anti-Bax was from Santa Cruz (Santa Cruz, CA, USA), anti-β-
actin from Sigma, anti-tubulin from Dunn Labortechnik (Asbach, Germany). Anti-
RIP1 and anti-PARP were purchased from BD Biosciences (Heidelberg, Germany).
Cell viability assay. Cells (4 × 104 per well) were seeded in 96-well plates and
challenged the next day with the indicated concentrations of TRAIL or Fc-CD95L in
triplicates. Cell viability was determined 18 h after stimulation using 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide staining.
Western blot analysis. Phosphorylation of proteins was analyzed as follows:
cells were harvested in medium, spun down, and were directly dissolved in 4x
Laemmli sample buffer (8% SDS, 0.1 M dithiothreitol, 40% (v/v) glycerol, 0.2 M Tris,
pH 8.0) supplemented with phosphatase inhibitor cocktails-I and -II (Sigma).
Subsequently, lysates were sonicated and boiled for 5 min at 96 °C. Protein
separation for western blot analyses was achieved by SDS-polyacrylamide gel
electrophoresis. After transfer to nitrocellulose membranes, nonspecific binding
sites were blocked by incubation in Tris-buffered saline containing 0.1% Tween 20
and 5% dry milk. Membranes were incubated with primary antibodies of the
specificity of interest. Antigen–antibody complexes were visualized using secondary,
horseradish peroxidase-conjugated antibodies (Dako, Hamburg, Germany) and the
ECL western blotting detection system (Pierce, Rockford, IL, USA).
For preparation of Triton X-100 lysates, cells were washed and resuspended in
lysis buffer (30 mM Tris–HCl, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 120 mM NaCl,
pH 5) supplemented with complete protease inhibitor cocktail (Roche Diagnostics
GmbH, Mannheim, Germany). After incubation for 20 min on ice, lysates were cleared
by centrifugation (20 min, 14 000 × g). After addition of Laemmli buffer, samples were
boiled for 5 min at 96 °C and separated by SDS-polyacrylamide gel electrophoresis.
siRNA transfection. Knockdown of caspase-9 was performed using siRNA
oligonucleotides (Qiagen, Hilden, Germany). Briefly, cells were seeded in six-well
plates (2.5 × 105 cells per well) and 200 pmol of caspase-9-specific or control siRNA
were transfected the next day using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. 48 h post-transfection, knock-
down efficacy was determined by western blot analysis.
Calculation of CI. The CI-values were calculated using the median effect/CI
isobologram method.13 In this model, CI-values o1 are considered to be
synergistic, whereas CI-value 41 indicate antagonistic effects. Synergistic effects
can be further graded based on the calculated CI-value: o0.1 very strong
synergism, 0.1–0.3 strong synergism, 0.3–0.7 synergism, 0.7–0.85 moderate
synergism, 0.85–0.9 slight synergism, 0.9–1.1 no synergism but nearly additive
effects.13 All CI calculations were performed using the freely available software
CompuSyn version 1.0.
Determination of IL-8 production. For measuring IL-8 secretion, cells
(2 × 104 per well) were seeded in 96-well tissue culture plates and cultured
overnight. Medium was changed and the indicated concentrations of TRAIL,
Fc-CD95L or medium were added for 6 h in the presence and absence of 100 μM
zVAD-fmk. The supernatant was collected and IL-8 was quantified using an ELISA
(BD Biosciences). All groups were analyzed as triplicates.
Densitometry. Intensities of protein bands were quantified using the open
source software ImageJ 1.47v (Wayne Rasband; National Institutes of Health,
Bethesda, MD, USA).
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